A Pfizer study of Marstacimab Prophylaxis received the green light before the Subject Expert Committee (SEC) to proceed with a Phase III Clinical Study. Marstacimab Prophylaxis is an anti-tissue factor pathway inhibitor (anti-TFPI), developed and being tested by Pfizer for patients with severe hemophilia A or B with or without inhibitors.
Phase two of Marstacimab has already shown promising results, as it showed significant reductions in the annualized bleed rate of all of the individuals in the study. Brenda Cooperstone, who is Pfizer's Chief Development Officer, Rare Disease, Global Product Development said: “Our approach to hemophilia research includes the investigation of multiple mechanisms to help address the needs of all people with hemophilia, including those with hemophilia A or B, and with or without inhibitors, and targeting TFPI provides a novel approach to improve blood coagulation. Based on the Phase II study findings to date, marstacimab may have the potential to offer improved bleed control via subcutaneous injection and potentially eliminate the need for prophylactic factor replacement, providing an enhanced treatment option compared to factor replacement therapy.”
Overall, the Hemophilia market is set to grow to a 19.1 billion dollar industry by 2027, which many physicians hope to see many breakthrough studies and medications for the hemophilia community.
Want to learn more about bleeding disorders? Sign up for our newsletter here! SIGN UP
Comments